Cathie Wood Sees 20% Returns After 'Unbelievable' 2020

Your EW knowledge is nice, but needs to perfect it, higher reliability must be there.

You have to train yourself to be 99% perfect predictions

I find is too slow for day/swing trading… by human interpretation, may be machine is faster. Good for short-term investing (i.e. more than 1 year). For day/swing trading, by observing just the price fluctuations, I can already guess without EW.

1 Like

I used to do manually but we err, machines are great ! Now, I do not buy anything without my machine!

1 Like

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Hims & Hers Health (HIMS)

His & Hers Health (HIMS), a newly public telemedicine company focused on removing the stigma associated with historically taboo health subjects, traded up 16% on Monday. The price action may have been caused by institutional investors building positions at the same time that Robinhood removed HIMS from its restricted list.

Castle Biosciences (CSTL)

Castle Biosciences (CSTL) traded up roughly 15% on Tuesday possibly in response to target price increases at both SVB Leerink and Canaccord Genuity. In addition, speculators may have purchased CSTL in anticipation of the Annual South Beach Symposium, during which Castle presented positive data on the performance of its DecisionDx-Melanoma test that improved risk-stratification for patients with smaller (T1) melanomas.

Codexis (CDXS)

Codexis (CDXS), a protein engineering company, closed up 15% on Tuesday perhaps because of increased investor confidence in its protein engineering platform, CodeEvolver. Recently, Google’s Deep Mind announced AlphaFold, a neural network-based algorithm that can predict protein folding, causing elevated interest in the space.

908 Devices (MASS)

908 Devices (MASS), an analytical tools company focused on decentralizing and lowering the cost of mass spectrometry, traded up nearly 16% on Tuesday, we believe in response to investors’ increased confidence in the more nascent proteomics space. Stifel, Cowen, and SVB Leerink all initiated on MASS with either ‘buy’ or ‘outperform’ ratings.

Virgin Galactic Holdings (SPCE)

Virgin Galactic Holdings (SPCE) was up 30% and 21% on Monday and Wednesday, respectively, after announcing the date of its new test flight window. Opening on February 13, the window is likely to provide several opportunities during the month to fly. The flight will test the answers to challenges that surfaced during the last test flight in December.

Agora Inc (API)

Agora Inc (API) rose 30% and 21% on Monday and Wednesday, respectively, seemingly in response to the rapid growth of Clubhouse, one of its increasingly popular customers. Agora is an API-based real-time-communications company in China enabling live video and voice engagements at large scale.

Cellectis (CLLS)

Cellectis (CLLS), a bio-pharmaceutical company that harnesses the power of TALENS, a gene-editing technique to create immunotherapies, traded down 20% on Wednesday on little news that we could discern.

Evogene (EVGN)

Evogene (EVGN), a computational biology company, closed up 16% on Thursday perhaps in response to news of the availability of call and put options on its stock.

Skillz (SKLZ)

Skillz (SKLZ) rose 25% on Thursday after announcing a deal with the National Football League (NFL) to develop a mobile NFL-themed game. The two sports organizations will host a competition for developers around the world to create an NFL-themed mobile game, ultimately with the hope of introducing hundreds of millions of NFL fans to the Skillz esports platform.

Twist Bioscience (TWST)

Twist Bioscience (TWST) fell approximately 17% on Friday after reporting fiscal first quarter results that outperformed analysts’ expectations on both the top and bottom lines but leaving 2021 revenue guidance unchanged. Moreover, its new manufacturing facility in Oregon could prevent gross margin expansion in 2021. Our confidence in Twist remains unchanged for multiple reasons. The company’s investments in capacity should contribute to margin expansion over the long-term, galvanized by secular growth in the synthetic biology and liquid biopsy markets. In addition, we believe Twist’s data-driven approach to target enrichment for next-generation sequencing (NGS) is best-in-class, especially for more esoteric biomarkers such as DNA methylation which are difficult to detect in liquid biopsies.

BILL (BILL) (BILL) rallied 25% on Friday after reporting strong results. BILL saw 59% core revenue growth, driven by a 33% increase in subscriptions and a 98% jump in transactions. Meanwhile continues to invest in R&D and channel partner products, expanding its total available market. automates back-office finance operations for small and medium sized businesses through its accounts payable software and B2B payments network.

1 Like

Archive link if you bumped into paywall:

According to FactSet, 43.5% of ARK’s total equity holdings are in stocks of which the firm owns at least a tenth of all shares outstanding. At Vanguard Group, by contrast, only 9.7% of total equity positions are in such concentrated holdings.

If ARK ever needs to sell any of those holdings, who will buy in enough bulk to keep prices from collapsing?

This is again using EW bottom! I just noticed the stock corrected 50% from peak using EW, bought it, now jumped 25% from bottom…they have two FDA approval pending…


Grayscale Bitcoin Investment Trust (GBTC)

20% Grayscale Bitcoin Investment Trust (GBTC), a trust tracking bitcoin’s market price, was up 20% on Monday after Tesla announced a $1.5 billion balance sheet investment - roughly 8% of its cash - into bitcoin. Tesla also said it would start accepting bitcoin as payment for its products. Tesla’s decision seems to be legitimizing bitcoin as corporate cash.

Longview Acquisition Corporation (LGVW)

18% Longview Acquisition Corporation (LGVW), a special purpose acquisition company (SPAC) that is acquiring Butterfly Network, closed up 18% on Monday. In our view, investors and speculators are building positions prior to the consummation of the merger on or around February 16th. Butterfly is a medical technology company focused on democratizing access to point-of-care ultrasound (POCUS) devices. Unlike other centralized and handheld POCUS instruments, Butterfly’s technology uses a proprietary semiconductor-based, AI-assisted ultrasound system instead of a system based on piezoelectric crystals. Butterfly’s technology seems to be a more cost-effective, robust, and differentiated tool for medical imaging.

ExOne (XONE)

16% ExOne (XONE), a global leader in additive manufacturing technology, appreciated more than 35% on Monday and 18% on Tuesday, before dropping 16% on Wednesday. ExOne preannounced revenues higher than consensus expectations for the fourth quarter as well as guidance for 2021 revenue growth of 15-25%, well above the 12.5% consensus expectation thanks to new products and increased demand. After the close on Tuesday, ExOne announced a secondary stock offering, pricing it on Wednesday at $54 per share.

Organovo (ONVO)

23% Organovo (ONVO), a biotechnology company focused on 3D-bioprinting, traded up 18% on Monday and 23% on Thursday, possibly because investors and speculators may be gaining confidence in its ability to maximize its 3D-bioprinting assets and deliver on a revitalized commercial strategy. We believe shares will be volatile until Organovo reveals more about its path forward.

Pacific Biosciences (PACB)

16% Pacific Biosciences (PACB), a leader in highly accurate and comprehensive DNA, RNA, and epigenetic sequencing, traded up 16% on Wednesday after disclosing that Softbank had invested $900 million via convertible debt. In our view, Softbank’s investment will allow PacBio to accelerate the cost- and price-decline of its highly accurate long-read technology (HiFi), pursue a more aggressive R&D schedule, and drive commercialization efforts faster than otherwise would be the case. HiFi sequencing should become the standard for whole genome sequencing across clinical, research, and population efforts, thanks to its accuracy, ability to phase mutations to maternal or paternal haplotypes, comprehensive variant detection, and native epigenetic detection. Though more expensive than short-read sequencing, the value of HiFi-sequenced genomes seems to be higher. As PacBio drives down prices and increases system throughput, many applications are likely to migrate to HiFi technology.

Ping An Healthcare and Technology (1833 HK)

21% Ping An Healthcare and Technology (1833 HK) rallied 21% on Wednesday, perhaps in response to its full year report and a number of Chinese broker ratings upgrades. Ping An Health is the largest online medical consulting firm in China based on total number of users and average daily queries.

Huya (HUYA)

19% Huya (HUYA) appreciated more than 19% on Thursday. The number one live game streaming platform in China, Huya currently is in talks with Douyu, the second-largest player in the space, with hopes to merge before mid-year

Zillow Group (ZG)

16% Zillow Group (ZG) rose 16% on Thursday after an exceptionally strong fourth quarter report and stronger than expected first quarter guidance. Zillow’s internal economist is projecting a 21% increase in US home sales this year thanks in part to a double-digit increase in prices. Zillow Group is the largest real estate marketplace in the US with more than 200 million monthly active users.

CM Life Sciences (CMLF)

15% CM Life Sciences (CMLF), a special purpose acquisition company (SPAC), surged 15**%** on Friday after announcing its plan to combine with Sema4, a population-scale health intelligence company. Unlike many legacy molecular diagnostics companies, Sema4 has focused on developing a platform instead of a diagnostic product. In our view, Sema4’s genomics acumen, epidemiological expertise, and emphasis on longitudinal patient care should yield a more engaging and effective experience for large health systems. Studying patient transitions from health to illness across large and diverse groups, Sema4 should be able to help physicians intervene before diseases become intractable.

HubSpot (HUBS)

16% HubSpot (HUBS) appreciated 16% on Friday after reporting better than expected fourth quarter earnings. HubSpot offers a full suite of digital solutions for businesses, including marketing, sales, and customer service tools. In its fourth quarter results, the company noted that it had surpassed two significant milestones: annual recurring revenue of $1 billion and 100,000 customers.

1 Like

Held in a buy n hold account. Since you mentioned, I took a look and an image.

1 Like

ZhongAn Online (6060 HK)

ZhongAn Online (6060HK) appreciated more than 32% on Tuesday in what we believe is a delayed response to results that suggest its heavy investment spending is paying off. ZhongAn is an online-only insurance company based in China that has expanded into new markets and products during the past few years. As a result of increased business activity and lower than expect underwriting losses, ZhongAn expects to report that it turned the corner from losses to a net profit for the full year in 2020.

Butterfly Network (BFLY)

Butterfly Network (BFLY), a medical technology company focused on democratizing access to point-of-care ultrasound (POCUS) devices, traded up nearly 17% on Wednesday after consummating its merger with Longview Acquisition Corporation (LGVW), a special purpose acquisition company (SPAC). In our view, investors are building positions in Butterfly as they learn more about its competitive advantages, particularly its application of federated learning and avoidance of piezoelectric crystal technology.

Yeahka (9923 HK)

Yeahka (9923HK), a QR-code based independent payment processing company in China, rose 26% on Wednesday, as part of a broad-based rally in China-based SaaS companies.

Fastly (FSLY)

Fastly (FSLY), an edge computing platform-as-a-service company, traded down 15% on Thursday despite reporting fourth quarter revenue and 2021 revenue guidance in line with expectations. The results were underwhelming on a sequential basis compared to those of its competitor, Cloudflare (NET), as well as on an organic basis excluding the contribution from Signal Sciences.

Organovo (ONVO)

Organovo (ONVO), a biotechnology company focused on 3D-bioprinting, traded down 15% on Thursday in a broad market selloff. We believe shares will remain volatile until Organovo reveals more about its path forward.

Stratasys (SSYS)

Stratasys (SSYS) closed down 15% during a broad-based market sell-off on Thursday after the company reported that it acquired RPS, a UK based stereolithography (SLA) 3D printing company, and plans to phase out its V650 Flex, an SLA 3D printer introduced in 2019.

ExOne (XONE)

ExOne (XONE) closed up more than 18% on Friday, perhaps in a delayed response to an announcement that it is developing a 3D printing factory housed in a shipping container for the Department of Defense (DoD).

Are you taking the recommendation from Cathie or news letter or just scanning what her team is buying?

I don’t think I ever bought anything purely based on Cathie’s buy list. I do find a lot of value reading her team’s research, and soaking in their general bullishness on technology and disruptions.

Their Big Ideas slide deck is a must read. It’s OK to disagree with their conclusions, but every investor should at least be aware of the trends they talked about.


FSLY and NET are not 100% competitors right? Just large overlap, right?

Glance through and forgot most of the content :hugs:

FSLY and NET are the top dogs fighting the war on next gen edge networks. NET seems to have the upper hand for the moment, but I think the market is large enough to have two players.

Time to read it again.


A bit late but still relavant:

It’s clear Cathie has three favorite kids in her portfolio: Tesla, Square and Roku. She keeps talking about them. For people who missed Tesla, (like me… :cry:) load up on SQ and ROKU instead.

Cathie also can’t stop badmouthing companies who please short term investors by issuing dividend and buying back stocks. Reminds me of a certain fruit company… :thinking:

Go for her TWST and CRSP with higher weightage than SQ and ROKU.

TSLA load up when you deep dip value , less than all the four above.

Lower the market cap higher the weightage !

1 Like

Sound obscene :joy: